



## Non-Hodgkin Lymphomas

Guest Editor:

### Prof. Dr. Pier Luigi Zinzani

1. IRCCS Azienda Ospedaliero-  
Universitaria di Bologna,  
Bologna, Italy.  
2. Istituto di Ematologia  
"Seràgnoli", Dipartimento di  
Medicina Specialistica,  
Diagnostica e Sperimentale  
Università degli Studi, Bologna,  
Italy

Deadline for manuscript  
submissions:

**closed (10 July 2022)**

### Message from the Guest Editor

Dear Colleagues,

Recently, new insights into the genetic/molecular basis of non-Hodgkin lymphomas have paved the way to the development of targeted therapies, and a better understanding of the interplay between the patient's immune system and cancer cells has led to the development of several innovative immunotherapies. Of these strategies, two that have recently generated much excitement are chimeric antigen receptor T-cell therapy and immune checkpoint inhibitors. The efficacy of these approaches is limited to a relatively small number of patients and, for this reason, there is an urgent need to identify positive or negative (bio)markers that predict treatment response or severe adverse events.

Prof. Dr. Pier Luigi Zinzani  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)